circadian clock comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
== As therapeutic targets == Modulation of PPI is challenging and is receiving increasing attention by the scientific community. Several properties of PPI such as allosteric sites and hotspots, have been incorporated into drug-design strategies. Nevertheless, very few PPIs are directly targeted by FDA-approved small-molecule PPI inhibitors, emphasizing a huge untapped opportunity for drug discovery. In 2014, Amit Jaiswal and others were able to develop 30 peptides to inhibit recruitment of telomerase towards telomeres by utilizing protein–protein interaction studies. Arkin and others were able to develop antibody fragment-based inhibitors to regulate specific protein-protein interactions. As the "modulation" of PPIs not only includes the inhibition, but also the stabilization of quaternary protein complexes, a paradigm introduced by the discovery of auxin-induced protein complex formation by Ning Zheng, molecules with this mechanism of action (so called molecular glues) are also extensively studied.
It would therefore appear desirable to process a material in such a way that it is physically uniform with regard to the distribution of components and porosity, rather than using particle size distributions which will maximize the green density. The containment of a uniformly dispersed assembly of strongly interacting particles in suspension requires total control over particle-particle interactions. A number of dispersants such as ammonium citrate (aqueous) and imidazoline or oleyl alcohol (nonaqueous) are promising solutions as possible additives for enhanced dispersion and deagglomeration. Monodisperse nanoparticles and colloids provide this potential. Monodisperse powders of colloidal silica, for example, may therefore be stabilized sufficiently to ensure a high degree of order in the colloidal crystal or polycrystalline colloidal solid which results from aggregation. The degree of order appears to be limited by the time and space allowed for longer-range correlations to be established. Such defective polycrystalline colloidal structures would appear to be the basic elements of sub-micrometer colloidal materials science, and, therefore, provide the first step in developing a more rigorous understanding of the mechanisms involved in microstructural evolution in high performance materials and components.
I do not know that it contains any branch of science which Congress would wish to exclude from their collection; there is, in fact, no subject to which a Member of Congress may not have occasion to refer. Jefferson's library was a working collection for a scholar, not for display. It doubled the size of the original library, transforming it from a specialist's library to a more general one. He organized his books based on Francis Bacon's organization of knowledge, grouping them into Memory, Reason, and Imagination with 44 subdivisions. The library used this scheme until the late 19th century when librarian Herbert Putnam introduced the Library of Congress Classification, now applying to over 138 million items. A February 24, 1824, report from the Committee of Ways and Means recommended a $5,000 appropriation for the Library of Congress, noting the need to improve its collections in "Law, Politics, Commerce, History, and Geography," which were crucial for Congress.
Sources: en.wikipedia.org
The system was deliberately developed using existing commercially available technology to speed introduction. The development team could not afford the time to develop and debug new technology. Watt, a pragmatic engineer, believed "third-best" would do if "second-best" would not be available in time and "best" never available at all. This led to the use of the 50 m wavelength (around 6 MHz), which Wilkins suggested would resonate in a bomber's wings and improve the signal. Unfortunately, this also meant that the system was increasingly blanketed by noise as new commercial broadcasts began taking up this formerly high-frequency spectrum. The team responded by reducing their own wavelength to 26 m (around 11 MHz) to get clear spectrum. To everyone's delight, and contrary to Wilkins' 1935 calculations, the shorter wavelength produced no loss of performance. This led to a further reduction to 13 m, and finally the ability to tune between 10 and 13 m, (roughly 30-20 MHz) to provide some frequency agility to help avoid jamming. Wilkins' method of height-finding was added in 1937. He had originally developed this system as a way to measure the vertical angle of transatlantic broadcasts while working at the RRS. The system consisted of several parallel dipoles separated vertically on the receiver masts. Normally the RDF goniometer was connected to two crossed dipoles at the same height and used to determine the bearing to a target return.
=== Space exploration === A direct search for life in Europa's ocean would today be prohibitively expensive. Impacts on Europa give us an easier way to look for evidence of life there. Every time a major impact occurs on Europa, a vast quantity of water is splashed from the ocean into the space around Jupiter. Some of the water evaporates, and some condenses into snow. Creatures living in the water far enough from the impact have a chance of being splashed intact into space and quickly freeze-dried. Therefore, an easy way to look for evidence of life in Europa's ocean is to look for freeze-dried fish in the ring of space debris orbiting Jupiter. Freeze-dried fish orbiting Jupiter is a fanciful notion, but nature in the biological realm has a tendency to be fanciful. Nature is usually more imaginative than we are. ...To have the best chance of success, we should keep our eyes open for all possibilities.
=== Carbamate nerve agents === While the carbamate acetylcholinesterase inhibitors are commonly referred to as "carbamate insecticides" due to their generally high selectivity for insect acetylcholinesterase enzymes over the mammalian versions, the most potent compounds such as aldicarb and carbofuran are still capable of inhibiting mammalian acetylcholinesterase enzymes at low enough concentrations that they pose a significant risk of poisoning to humans, especially when used in large amounts for agricultural applications. Other carbamate based acetylcholinesterase inhibitors are known with even higher toxicity to humans, and some such as T-1123 and EA-3990 were investigated for potential military use as nerve agents. However, since all compounds of this type have a quaternary ammonium group with a permanent positive charge, they have poor blood–brain barrier penetration, and also are only stable as crystalline salts or aqueous solutions, and so were not considered to have suitable properties for weaponisation.
=== Felim Bichan === Felim Bichan (Andrew Buchan) is a Scottish hedge fund manager and initially Pierpoint's biggest client with a decades-long client relationship with Eric. A firm, principled man who ascended from humble beginnings, Felim initially cuts ties with Eric and Pierpoint after Eric drunkenly makes offensive comments in front of Felim's wife. On Eric's orders, Harper attempts to coax Felim back to the firm, but Felim gently warns Harper not to fall prey to Eric's malign influence. In series 2, Felim returns as Pierpoint's client so long as Harper act the intermediary between him and Eric. Harper, however, blows off a client meeting with Eric and Felim to meet with notorious independent investor Jesse Bloom, who she is courting as a client. Felim is initially the anchor on a $3.3 billion block trade for shares of healthcare startup Rican, with Eric promising him pre-buy stock options. Felim, however, pulls out of the trade after Harper misses the client meeting, as it reaffirms his distrust of Eric, and Harper sells the shares to Bloom at the last minute instead. Felim, Jesse, Harper and Eric attend a duck shoot in Wales for Rican investors, which Pierpoint initially organized to celebrate Felim's planned purchase of Rican stock. Felim and Jesse remain at odds since Felim rejects his modest beginnings while Jesse embraces his, and Felim chastises Harper for gravitating towards bullies. Jesse later injures Felim's face with shrapnel while trying to shoot a rare pheasant.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.